NCT02072018View on ClinicalTrials.gov

Peyronie's Disease Treatment Protocol

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Peyronie's Disease
Interventions
DRUG

H-100

H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.

DRUG

Placebo

Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.

Trial Locations (1)

55422

North Memorial Medical Center, Robbinsdale

Sponsors

Lead Sponsor

Hybrid Medical
All Listed Sponsors
lead

Hybrid Medical

INDUSTRY